VB 10.2129
Alternative Names: VB10.2129Latest Information Update: 03 Dec 2021
At a glance
- Originator Vaccibody
- Developer Nykode Therapeutics
- Class COVID-19 vaccines; DNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 23 Nov 2021 Vaccibody is now called Nykode Therapeutics
- 27 Oct 2021 Phase-I/II clinical trials in COVID-2019 infections (Prevention) in Norway (IM) (NCT05069623)
- 12 Oct 2021 Preclinical trials in COVID-2019 infections (In volunteers) in Norway (IM) (Vaccibody pipeline, October 2021)